Form 4: NeuroPace Director Rakhi Kumar Granted Stock Options Valued at $13.15 Per Share

NeuroPace Inc. Director Rakhi Kumar was granted 8,745 stock options with an exercise price of $13.15, vesting monthly over one year, as disclosed in a recent SEC Form 4 filing.

Summary

• Rakhi Kumar, a Director of NeuroPace Inc. (NPCE), was granted 8,745 stock options.
• The transaction date for this grant was June 6, 2025.
• Each stock option has an exercise price of $13.15.
• The options are set to vest in twelve equal consecutive monthly installments.
• Vesting is contingent upon Ms. Kumar's continuous service through each vesting date.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Ms. Kumar beneficially owns 8,745 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholders, but it is a routine compensation matter and not indicative of significant operational or financial changes.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity-based compensation is a common practice for attracting and retaining experienced board members.

Negatives

• The grant of options does not represent an immediate cash inflow for the company.

Risks

• The value of the stock options is dependent on the future market price of NeuroPace Inc. common stock; if the stock price does not exceed the exercise price of $13.15, the options may not be exercised.
• The vesting schedule requires continuous service, meaning the options could be forfeited if the director's service terminates before full vesting.

Future Outlook

The vesting schedule of the stock options, occurring in twelve equal consecutive monthly installments, indicates an expectation of continued service from Director Rakhi Kumar for at least one year from the grant date.

Industry Context

The grant of stock options is a standard component of director compensation packages across various industries, including the medical device and biotechnology sectors where NeuroPace operates. This practice is designed to align the interests of board members with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this Form 4, equity grants to directors are a common compensation mechanism in the medical technology industry, similar to practices observed at companies like Medtronic, Boston Scientific, or Abbott Laboratories, though the specific size and terms of grants vary based on company size, performance, and board structure.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Rakhi Kumar constitutes a related party transaction, as it involves the company providing compensation to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest in twelve equal consecutive monthly installments, subject to continuous service.

Key Dates

Keywords

NeuroPace, NPCE, Rakhi Kumar, Stock Option, Form 4, Insider Transaction, Equity Grant, Director Compensation, SEC Filing